BIOMAT Database Logo BIOMAT Database Logo

[Preoperative treatment of hypoglycemia caused by an insulinoma with the somatostatin analog SMS 201-995]. 1987

P Sánchez García Cervigón, and J I Fernández Navarro, and J Salmerón de Diego, and A Caballero Asensi, and F Cornelio Hernández, and A Jara Albarrán

UI MeSH Term Description Entries
D007003 Hypoglycemia A syndrome of abnormally low BLOOD GLUCOSE level. Clinical hypoglycemia has diverse etiologies. Severe hypoglycemia eventually lead to glucose deprivation of the CENTRAL NERVOUS SYSTEM resulting in HUNGER; SWEATING; PARESTHESIA; impaired mental function; SEIZURES; COMA; and even DEATH. Fasting Hypoglycemia,Postabsorptive Hypoglycemia,Postprandial Hypoglycemia,Reactive Hypoglycemia,Hypoglycemia, Fasting,Hypoglycemia, Postabsorptive,Hypoglycemia, Postprandial,Hypoglycemia, Reactive
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007340 Insulinoma A benign tumor of the PANCREATIC BETA CELLS. Insulinoma secretes excess INSULIN resulting in HYPOGLYCEMIA. Adenoma, beta-Cell,Insuloma,beta-Cell Tumor,Adenoma, beta Cell,Adenomas, beta-Cell,Insulinomas,Insulomas,Tumor, beta-Cell,Tumors, beta-Cell,beta Cell Tumor,beta-Cell Adenoma,beta-Cell Adenomas,beta-Cell Tumors
D007516 Adenoma, Islet Cell A benign tumor of the pancreatic ISLET CELLS. Usually it involves the INSULIN-producing PANCREATIC BETA CELLS, as in INSULINOMA, resulting in HYPERINSULINISM. Islet Cell Tumor,Islet of Langerhans Tumor,Nesidioblastoma,Pancreatic Islet Cell Tumors,Island Cell Tumor,Adenomas, Islet Cell,Island Cell Tumors,Islet Cell Adenoma,Islet Cell Adenomas,Islet Cell Tumors,Langerhans Tumor Islet,Nesidioblastomas,Tumor Islet, Langerhans,Tumor, Island Cell,Tumor, Islet Cell,Tumors, Island Cell,Tumors, Islet Cell
D010190 Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). Cancer of Pancreas,Pancreatic Cancer,Cancer of the Pancreas,Neoplasms, Pancreatic,Pancreas Cancer,Pancreas Neoplasms,Pancreatic Acinar Carcinoma,Pancreatic Carcinoma,Acinar Carcinoma, Pancreatic,Acinar Carcinomas, Pancreatic,Cancer, Pancreas,Cancer, Pancreatic,Cancers, Pancreas,Cancers, Pancreatic,Carcinoma, Pancreatic,Carcinoma, Pancreatic Acinar,Carcinomas, Pancreatic,Carcinomas, Pancreatic Acinar,Neoplasm, Pancreas,Neoplasm, Pancreatic,Neoplasms, Pancreas,Pancreas Cancers,Pancreas Neoplasm,Pancreatic Acinar Carcinomas,Pancreatic Cancers,Pancreatic Carcinomas,Pancreatic Neoplasm
D011292 Premedication Preliminary administration of a drug preceding a diagnostic, therapeutic, or surgical procedure. The commonest types of premedication are antibiotics (ANTIBIOTIC PROPHYLAXIS) and anti-anxiety agents. It does not include PREANESTHETIC MEDICATION. Premedications
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013004 Somatostatin A 14-amino acid peptide named for its ability to inhibit pituitary GROWTH HORMONE release, also called somatotropin release-inhibiting factor. It is expressed in the central and peripheral nervous systems, the gut, and other organs. SRIF can also inhibit the release of THYROID-STIMULATING HORMONE; PROLACTIN; INSULIN; and GLUCAGON besides acting as a neurotransmitter and neuromodulator. In a number of species including humans, there is an additional form of somatostatin, SRIF-28 with a 14-amino acid extension at the N-terminal. Cyclic Somatostatin,Somatostatin-14,Somatotropin Release-Inhibiting Hormone,SRIH-14,Somatofalk,Somatostatin, Cyclic,Somatotropin Release-Inhibiting Factor,Stilamin,Somatostatin 14,Somatotropin Release Inhibiting Factor,Somatotropin Release Inhibiting Hormone

Related Publications

P Sánchez García Cervigón, and J I Fernández Navarro, and J Salmerón de Diego, and A Caballero Asensi, and F Cornelio Hernández, and A Jara Albarrán
[Management of insulinoma with the somatostatin analog SMS 201-995].
April 1988, Medicina clinica,
P Sánchez García Cervigón, and J I Fernández Navarro, and J Salmerón de Diego, and A Caballero Asensi, and F Cornelio Hernández, and A Jara Albarrán
Hypoglycemia after administration of somatostatin analog (SMS 201-995) in metastatic carcinoid.
January 1989, Henry Ford Hospital medical journal,
P Sánchez García Cervigón, and J I Fernández Navarro, and J Salmerón de Diego, and A Caballero Asensi, and F Cornelio Hernández, and A Jara Albarrán
[Treatment of pancreatic apudomas with a somatostatin analog SMS 201-995].
December 1988, Medicina clinica,
P Sánchez García Cervigón, and J I Fernández Navarro, and J Salmerón de Diego, and A Caballero Asensi, and F Cornelio Hernández, and A Jara Albarrán
Treatment of acromegaly with the long-acting somatostatin analog SMS 201-995.
January 1988, The Journal of clinical endocrinology and metabolism,
P Sánchez García Cervigón, and J I Fernández Navarro, and J Salmerón de Diego, and A Caballero Asensi, and F Cornelio Hernández, and A Jara Albarrán
Treatment of inappropriate secretion of thyrotropin with somatostatin analog SMS 201-995.
January 1988, Hormone research,
P Sánchez García Cervigón, and J I Fernández Navarro, and J Salmerón de Diego, and A Caballero Asensi, and F Cornelio Hernández, and A Jara Albarrán
Treatment of severe reactive hypoglycemia with a somatostatin analogue (SMS 201-995).
November 1990, Archives of internal medicine,
P Sánchez García Cervigón, and J I Fernández Navarro, and J Salmerón de Diego, and A Caballero Asensi, and F Cornelio Hernández, and A Jara Albarrán
[Pharmacological treatment of gastroenteropancreatic apudomas with an analog of somatostatin, SMS 201-995 (octreotide)].
February 1991, Revista espanola de enfermedades digestivas,
P Sánchez García Cervigón, and J I Fernández Navarro, and J Salmerón de Diego, and A Caballero Asensi, and F Cornelio Hernández, and A Jara Albarrán
[The somatostatin analog SMS 201-995 in long-term treatment of vipoma].
December 1990, Ugeskrift for laeger,
P Sánchez García Cervigón, and J I Fernández Navarro, and J Salmerón de Diego, and A Caballero Asensi, and F Cornelio Hernández, and A Jara Albarrán
Recognition by goby intestine of a somatostatin analog, SMS 201-995.
January 1990, The Journal of experimental zoology. Supplement : published under auspices of the American Society of Zoologists and the Division of Comparative Physiology and Biochemistry,
P Sánchez García Cervigón, and J I Fernández Navarro, and J Salmerón de Diego, and A Caballero Asensi, and F Cornelio Hernández, and A Jara Albarrán
Excessive grooming induced by somatostatin or its analog SMS 201-995.
December 1987, European journal of pharmacology,
Copied contents to your clipboard!